Cronol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cronol

Property Description
Active ingredient Famotidine
Form Tablet, Solution, Suspension
Pharmacological class Histamine H2-receptor antagonist
General purpose Gastric acid suppression
Origin Synthetic compound

Cronol is a pharmaceutical preparation whose primary component is the synthetic chemical entity Famotidine, officially classified as a Histamine H2-receptor antagonist (H2-blocker). This places it within the therapeutic category of antisecretory agents designed to manage conditions arising from excessive gastric acid production. The formulation is clinically recognized for its ability to reduce acid secretion effectively.


What Type of Medicine is Cronol? (Definition and Classification)

Cronol is an antisecretory agent that works by controlling the natural acid-producing signals within the stomach lining. Its active substance, Famotidine, is a small, synthetic compound that functions as a selective competitive inhibitor of histamine at the parietal cell receptor sites. This targeted action distinguishes it from simple antacids, which neutralize existing acid. H2-blockers like Famotidine proactively suppress the creation of new acid, providing a more sustained effect; this means the medicine works to actively reduce the amount of acid the stomach produces.


Composition and Physical Forms

Cronol is manufactured as a single-ingredient product, containing only the active substance Famotidine. The medication is available in several dosage forms, most commonly as an oral tablet and a chewable tablet, facilitating administration via the oral route for convenience. The preparation is also supplied as an oral suspension and a sterile solution for parenteral (intravenous) administration, ensuring flexibility in delivery across various patient needs. Famotidine is characterized as a potent, long-acting H2-receptor blocker, supporting the management of acid levels over an extended period.


General Purpose and Mechanism Principle

The general therapeutic purpose of Cronol is to achieve gastric acid suppression by interrupting the acid production cycle. It functions by occupying the stomach's H2-receptors, thereby preventing the natural chemical signal, histamine, from reaching its target and stimulating acid release. This mechanism works to alleviate the burning sensations, irritation, and general discomfort caused by excessive or rising stomach acid, regardless of the specific underlying cause.

Regulatory References

  1. Famotidine - StatPearls - NCBI Bookshelf
  2. Famotidine: MedlinePlus Drug Information

What side effects are possible with Cronol?

Possible Side Effects and Safety Information

The official safety profile of Cronol (Famotidine) defines potential adverse reactions by their likelihood and the body systems affected, based on data compiled by government regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to their observed frequency in clinical use:

Classification Examples of Documented Adverse Reactions
Common Headache, dizziness, constipation, and diarrhea.
Uncommon Nausea, vomiting, abdominal discomfort, fatigue, and rash.
Rare Serious hypersensitivity reactions like anaphylaxis and angioedema.

System-Organ Classes and Serious Events

Adverse effects are documented across several System-Organ Classes. Common reports involve Gastrointestinal Disorders and Nervous System Disorders. Other documented classes include Skin and Subcutaneous Tissue Disorders and Blood and Lymphatic System Disorders.

Regulatory documents also list serious adverse reactions, which are rare but clinically significant. These include severe Blood Dyscrasias (such as agranulocytosis) and rare Hepatobiliary Disorders (such as cholestatic jaundice).


Population-Specific Safety Considerations

The official label highlights specific safety notes for certain patient populations. Individuals with renal impairment and older adults are noted to have an increased susceptibility to Central Nervous System (CNS) adverse effects, such as confusion and disorientation, due to reduced plasma clearance of the medicine. The risk of cardiac rhythm abnormalities like QT prolongation is more frequently associated with the intravenous form, particularly in patients with pre-existing renal impairment.

Symptomatic response to this medicine does not preclude the presence of an underlying gastric malignancy; further clinical investigation is required when appropriate.

Overdose and Emergency Response

The official regulatory profile for Cronol overdose is defined by the spectrum of documented manifestations and mandated emergency actions. Overdose presentations are generally reported to be similar to the adverse reactions experienced during regular use, such as dizziness, headache, or diarrhea.


Documented Severe Outcomes and Required Actions

Domain Official Regulatory Statement
Severe Outcomes High exposure can lead to Central Nervous System (CNS) adverse reactions, including seizures, confusion, delirium, and hallucinations. Serious cardiac effects, such as QT prolongation and arrhythmias, are also noted.
Mandated Emergency Action In case of overdose, seek medical help or contact a Poison Control Center right away. Urgent intervention is required; immediately call emergency services if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management and Population Risk

Management involves applying clinical monitoring and supportive therapy, including the usual measures to remove unabsorbed material from the gastrointestinal tract. A specific antidote for Cronol overdose is not documented in the official prescribing information. Regulatory documents specify an elevated risk of severe CNS adverse reactions for elderly patients and individuals with moderate to severe renal impairment due to increased systemic exposure.

Therapeutic Uses of Cronol

What Cronol treats: main uses and benefits

Cronol is an antisecretory agent primarily used to manage conditions and provide relief across domains driven by excessive gastric acid production. Its therapeutic applications are used in situations involving certain distressing symptoms and recognized clinical needs.

The medicine plays a role in managing serious conditions like active gastric and duodenal ulcers and acid-induced tissue damage, such as erosive esophagitis. It is also applied in scenarios where short-term symptomatic assistance is needed to manage the sudden, disruptive burning sensation in the chest (heartburn), and generalized discomfort of acid indigestion. In chronic cases, it is considered relevant for conditions characterized by periods of heightened physiological activity leading to extreme acid excess, such as Zollinger-Ellison Syndrome.

Used in conditions associated with gastric acid, Cronol supports the healing of painful lesions and may be part of symptomatic management for reducing the likelihood of ulcer recurrence. This therapeutic approach provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.

Therapeutic Context Focus
Cronol is commonly used to help with episodic heartburn and to support the healing of active duodenal ulcers, supporting the management of key symptoms related to upper GI irritation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cronol?

This section summarizes the official population eligibility and non-eligibility information for Cronol (high-concentration fluoride toothpaste), strictly based on governmental regulatory documents.


Eligibility and Exclusion Summary

Population Group Regulatory Status
Eligible for Use Adults and adolescents aged 16 years and over.
Strictly Contraindicated Children and adolescents aged under 16 years.
Absolute Contraindication Individuals with known hypersensitivity to the active substance or any excipients.

Formal Contraindications

Use of Cronol is formally contraindicated and must be avoided in the following groups:

  • Age Restriction: Individuals under the age of 16 years.
  • Allergy Risk: Patients with known hypersensitivity or allergic reaction to sodium fluoride or any other ingredient.
  • Comorbidity: Patients with rare hereditary problems of fructose intolerance due to the presence of the excipient sorbitol solution.

Conditional Use and Restrictions

Certain populations require a professional assessment before use, or the use is not generally recommended:

  • Pregnancy and Lactation (Breastfeeding): Use is not recommended unless a careful risk-benefit assessment has been carried out by a healthcare professional.
  • Systemic Fluoride Intake: A dental specialist must assess the patient’s total cumulative fluoride intake (from water, tablets, drops, etc.) before prescribing to mitigate the risk of fluorosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section explains the formally documented interaction patterns for Cronol (Famotidine), strictly based on authoritative government regulatory sources.

Interaction Scope

Detail Description
Medicinal product categories Drugs dependent on gastric pH for absorption; CYP1A2 substrates.
Specific interacting medicines Tizanidine (listed as a CYP1A2 substrate).
Mechanistic basis Pharmacokinetic interaction (interference with pH-dependent absorption and CYP1A2 enzyme interaction); reduced systemic clearance in specific populations.
Population-specific notes Renal Impairment (moderate/severe) and Elderly Patients exhibit increased systemic exposure, raising the documented risk of Central Nervous System adverse reactions.
Interaction-related restrictions Co-administration with Tizanidine is documented as a combination to avoid due to the potential for substantial increases in Tizanidine plasma concentrations.

Resulting Interaction Structure

Official interaction statements:

  • The pharmacokinetic interaction stemming from acid suppression may cause a significant reduction in the systemic exposure of co-administered medicines that require an acidic environment for absorption, resulting in a potential loss of efficacy.
  • A distinct pharmacokinetic effect is the interaction with the CYP1A2 enzyme pathway, which leads to substantially increased plasma concentrations of Tizanidine. This increase is the basis for the regulatory constraint to avoid concomitant use.
  • In specific populations, including those with renal impairment and elderly patients, official data shows reduced clearance of Famotidine, which results in elevated systemic exposure and an amplified risk of documented CNS effects.
  • No clinically significant interaction has been documented with food, and no mandatory administration separation is specified for the identified interacting substances.

Connection to the overall interaction profile:

The regulatory documentation establishes that Cronol's interaction structure is primarily governed by two distinct pharmacokinetic effects: one leading to reduced exposure of co-administered drugs sensitive to gastric pH, and another leading to increased exposure of Tizanidine via CYP1A2 interaction. The documentation further notes that the drug's own clearance capacity in renally impaired or elderly patients creates a population-specific context for increased systemic exposure risk.

Mechanism of Action

How Cronol Works — Mechanism of Action

Cronol (Famotidine) acts exclusively within the pharmacodynamic domain of receptor-mediated signaling to modulate gastric acid secretion. Its mechanism is initiated by functioning as a selective competitive antagonist at the Histamine H2 Receptors ( H2R) located on the basolateral membrane of the gastric parietal cell .

This binding physically blocks the natural chemical messenger, histamine, from activating the receptor. The resulting receptor blockade functionally interrupts the intracellular signaling cascade by suppressing the rise of the second messenger, cyclic adenosine monophosphate (cAMP). This prevents the activation of Protein Kinase A (PKA), which is necessary to mobilize and activate the terminal acid-secreting enzyme, the H^+/ K^+-ATPase (Proton Pump).

This specific molecular action results in a substantial decrease in both the volume of gastric fluid and the concentration of hydrochloric acid (HCl) within the stomach lumen. The mechanism modulates acid output by reducing both the basal (resting) and stimulated (triggered) release of acid by the stomach lining, operating entirely at the level of glandular secretion control.

Dosage and Administration Information

How to use Cronol

Cronol is administered through two methods: the oral route, utilizing tablets, chewable tablets, and liquid forms, and the parenteral (intravenous) route, which is generally reserved for patients in hospital settings who are unable to tolerate oral administration. The frequency and dosage of the medicine are determined by the specific condition being managed, a principle known as dose-to-condition alignment. For conditions such as active ulcers, the standard adult oral dosing often involves a regimen of 20 mg taken twice daily, or 40 mg administered once daily at bedtime. For pathological hypersecretory conditions, the initial dosage starts at 20 mg every six hours and may be adjusted to control acid levels, with maximum total daily doses reaching up to 640 mg.

Usage patterns over time are defined based on the condition. For most acute conditions, Cronol is used as a short-term treatment, typically spanning four to twelve weeks. Maintenance therapy to reduce the risk of ulcer recurrence may be part of a long-term plan, continuing for up to one year. Over-the-counter use for self-treatment of heartburn is limited to a maximum duration of 14 consecutive days. Regarding administration, oral forms may be taken with or without food. Key procedural instructions include the requirement to shake the oral suspension vigorously before use and the mandate that IV doses must be injected slowly over at least two minutes. Furthermore, for patients with severe renal impairment (creatinine clearance less than 30 mL/min), a dose reduction of 50% or an extended dosing interval is required to prevent accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cronol


Evidence for Healing Active Ulcers (Duodenal and Gastric)

The research exploring Cronol's use in managing active ulcers is largely based on short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and often included adults who had endoscopically confirmed ulcers. Researchers monitored the endoscopic ulcer healing rate at defined intervals and tracked patient-reported outcomes describing perceived discomfort. Studies report patterns where the rate of observed healing was notably different compared to placebo, with findings describing that a majority of observed patients achieved healing within the typical short-term study duration.

What remains uncertain is the full extent of comparative data when assessed directly against all newer classes of acid-reducing medicines. The findings reflect patterns observed only over a limited short-term follow-up of up to eight weeks and do not characterize the long-term status of the healed tissue.


Evidence for Managing Symptomatic Reflux and Esophagitis

For conditions like heartburn and erosive esophagitis, the evidence relies on RCTs that evaluated single doses for acute relief and short courses of therapy. Studies monitored outcomes linked to inflammatory or irritative states. For episodic heartburn, researchers measured the rate and speed of symptom relief. For erosive esophagitis, studies tracked the healing of visible irritative states. Evidence in some studies highlights that the initial severity of esophagitis may be associated with the variability in results.

Evidence is limited for long-term outcomes for patients with non-erosive GERD. Furthermore, the effectiveness observed for healing severe esophagitis has been noted in some studies to vary when compared to other available classes of acid-reducing drugs, suggesting that the degree of certainty remains low for the most severe cases.

Key Studies & References

  1. Famotidine for oral suspension (DailyMed): Full prescribing information detailing indications and clinical study durations.
  2. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer (European Journal of Gastroenterology & Hepatology / NCBI)
  3. Famotidine - StatPearls (NCBI Bookshelf): Review of clinical use, dosing, and special populations (pregnancy, renal impairment).

Frequently Asked Questions (FAQ)

Common questions about Cronol (FAQ)

Q: What is the main condition Cronol is officially approved to treat?

A: According to official product information, Cronol (Famotidine) is approved for managing conditions resulting from excessive stomach acid. These include active ulcers (duodenal and gastric), gastroesophageal reflux disease (GERD), erosive esophagitis, and pathological hypersecretory conditions like Zollinger-Ellison Syndrome.

Q: Is there any research evidence on the long-term use of Cronol?

A: Studies have shown that Cronol is effective for short-term treatment of acute conditions. While official documents define treatment limits for these acute uses, they also describe the existence of maintenance therapy regimens to help prevent the recurrence of ulcers, indicating a context for longer-term, monitored use.

Q: I heard Cronol can affect your sleep. Is that a common concern?

A: Official product safety information indicates that sleep disturbances are a documented adverse reaction. Specifically, insomnia (difficulty sleeping) and somnolence (unusual drowsiness) are listed among the possible side effects of the medicine.

Q: Are there any known common interactions between Cronol and over-the-counter pain relievers?

A: Regulatory text advises patients to inform their healthcare provider about all medications, including over-the-counter pain relievers like NSAIDs. Regulatory information indicates that caution is necessary when using Cronol with NSAIDs, as these pain relievers may potentially worsen the underlying acid-related condition being treated.

Q: What does the patient information leaflet say about missed doses?

A: The official patient information leaflet describes a recommended procedure for a missed dose. It states that the dose may be taken as soon as possible, but if it is almost time for the next scheduled dose, the missed one should be skipped. Patients are advised not to take double or extra doses.

Q: Does Cronol need to be taken at a specific time of day?

A: According to the official dosing examples, Cronol is frequently prescribed to be taken once or twice daily, sometimes specifically in the morning or at bedtime. The precise timing is typically decided by a healthcare provider based on the condition being addressed and the individual patient requirements.

Q: How long does it usually take to notice the described effects of Cronol?

A: Studies suggest that the acid-suppressing effect of Cronol generally begins within one hour after oral administration. The peak acid-blocking effect is commonly observed between one to three hours, according to clinical pharmacology studies.

Q: Can Cronol be used by older adults?

A: Cronol is permitted for use by older adults, but regulatory warnings exist regarding this population. Due to reduced clearance, individuals aged 65 years and older may have an increased risk of Central Nervous System (CNS) adverse reactions, such as confusion or disorientation.

Q: What is the generally expected duration of the effects of Cronol?

A: Clinical pharmacology studies involving standard doses indicate that the acid-suppressing effects of Cronol are sustained. For a typical 20 mg or 40 mg dose, the therapeutic effect is generally expected to last approximately 10 to 12 hours.

Q: Could my herbal supplement or multivitamin interact with Cronol?

A: Official patient information emphasizes the importance of providing a healthcare provider with a complete list of all medicines, herbs, dietary supplements, and vitamins being taken. This precautionary measure is essential because some of these products may interfere with the action of Cronol or its absorption.

Q: Is Cronol described as having a risk of dependence?

A: No, official regulatory and medical database information states that Cronol (Famotidine) is not classified as a controlled substance. The medicine is not associated with physical dependence, potential for abuse, or withdrawal symptoms.

Q: Are there any specific lab tests that are recommended while using Cronol?

A: Official precautions in regulatory documents note that specific lab tests may be recommended during treatment with Cronol. Blood and urine tests may be used at regular intervals to monitor the patient’s progress and check for potential unwanted effects.

Q: Does Cronol interact with alcohol, according to official documents?

A: Regulatory texts generally do not list a direct chemical interaction between Cronol and alcohol. However, it is noted that alcohol is generally known to worsen acid-related conditions and symptoms, which may counteract the medicine's therapeutic effect.

Q: What is the description of the effect of Cronol on alertness?

A: The official safety profile includes adverse effects that can influence alertness. These include dizziness, somnolence (unusual drowsiness), and sometimes confusion. The safety profile indicates these effects may be relevant when performing tasks that require concentration.

Q: Can Cronol be used by people who have mild kidney concerns?

A: Use is conditional upon review by a healthcare provider. Official documents require dose adjustments, either a reduced dose or a change in dosing interval, for patients with moderate or severe kidney impairment. This adjustment is necessary to prevent the medicine from accumulating in the body and causing side effects.

Q: Is Cronol suitable for people with a history of heart issues?

A: Official warnings note a rare risk of cardiac rhythm abnormalities, specifically prolonged QT interval, associated with Cronol. This risk is primarily linked to the intravenous form of the medicine and is heightened in patients who also have pre-existing kidney concerns.

Q: Does Cronol treat the cause of the condition or just the symptoms?

A: Cronol primarily works by suppressing the production of stomach acid, which alleviates the symptoms of acid-related conditions. Regulatory documents specifically warn that the symptomatic relief provided by the drug does not rule out the presence of a more serious, underlying issue, such as a gastric malignancy.

Q: Is the full benefit of Cronol noticeable right away, or does it take time?

A: While patients may feel initial symptom relief within an hour of taking the medicine, the full therapeutic benefit for healing conditions like ulcers or erosive esophagitis takes time. The healing process is typically assessed over the entire prescribed course of therapy, which can be several weeks long.

Q: Is the mechanism of Cronol fully understood and described in official documents?

A: Yes, the official documentation describes the medicine's mechanism in great detail. It explains that Cronol works as a competitive antagonist at the histamine H2 receptors on the parietal cells, a targeted action that successfully suppresses stomach acid secretion.

Q: Is it true that Cronol might cause dry mouth?

A: Yes, dry mouth is a documented adverse reaction in the official safety profile for Cronol. It is typically classified as an uncommon or rare side effect.

Q: I read that Cronol is metabolized by the liver; what does that imply?

A: Cronol is primarily cleared from the body by the kidneys, but regulatory documents do note that it interacts with the CYP1A2 enzyme system. This enzyme system can be involved in the metabolism of other medications, and the interaction can lead to increased blood levels of certain co-administered drugs.

Q: Are there warnings about driving or operating machinery while using Cronol?

A: Due to potential side effects like dizziness or confusion, official warnings indicate that patients should assess their reaction to Cronol before they operate a car or heavy machinery.

Q: Does Cronol have any known interactions with birth control pills?

A: No specific drug interaction between Cronol and oral contraceptives is typically highlighted in the regulatory text. General regulatory guidance emphasizes that a complete list of all medications should always be provided to the prescribing physician.

Q: Does Cronol affect blood pressure according to the product labeling?

A: Low blood pressure (hypotension) is not listed as a common general side effect in the product labeling. However, it is noted as a potential adverse event risk when Cronol interacts with certain other drugs, such as Tizanidine, in combination use.

Q: Can Cronol be used alongside other medicines that treat the same condition?

A: Official labeling indicates that Cronol has been studied and may be used in certain combination therapies, for example, to help reduce the gastrointestinal effects caused by NSAID medications. Any decision regarding the use of Cronol alongside other treatments for the same condition is subject to a review by a healthcare professional.

Q: What are the main criteria for being eligible to receive a prescription for Cronol?

A: The primary criteria for eligibility are the approved indications found in the regulatory documents. These are the presence of a diagnosable condition that Cronol is indicated to treat, such as an active ulcer, GERD, erosive esophagitis, or pathological hypersecretory conditions.

Q: Is Cronol known to cause weight changes?

A: Weight gain is not listed as a direct side effect in the official product labeling. However, authoritative sources note that individuals may experience some weight change due to the medicine successfully reducing stomach pain and indigestion, which can lead to improved appetite.

Q: Does Cronol interact with commonly prescribed antidepressants?

A: Yes, official drug interaction warnings exist regarding the use of Cronol with certain classes of antidepressants, such as SSRIs (Selective Serotonin Reuptake Inhibitors). The combination can potentially lead to an increased risk of gastrointestinal bleeding.

How should Cronol be stored and disposed of?

How to Store and Dispose of Cronol?

The official labeled instructions define precise conditions for storing and discarding Cronol (Famotidine) to maintain its stability and ensure safety. Storage must adhere to a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with regulatory limits stating that tablets should not be stored above 25 C.

Mandatory Storage and Stability

Requirement Constraint
Temperature Store at room temperature; do not freeze the liquid form.
Protection Keep in the original, tightly closed container away from excess heat, light, and moisture.
Stability Limit The oral liquid (suspension) must be discarded 30 days after opening or preparation.
Child Safety Mandatory to keep the medicine out of the sight and reach of children.

Official Disposal Instructions

Used or expired Cronol should be disposed of through an authorized drug take-back program when available. Official guidelines advise against throwing the medicine into household waste or flushing it down a toilet, unless a take-back program is unavailable, in which case it should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cronol found in:

A-Z Index: